Abcam, ab94216, Alpha 1 Acid Glycoprotein overexpression 293T lysate (whole cell)

Size: 100µL
Alpha 1 Acid Glycoprotein overexpression 293T lysate (whole cell) suitable for WB. View our extensive range of validated lysates from normal and diseased human, mouse and rat tissue.
Key facts
Species or organism:Human,
Form:LiquidSee storage information

Product details:
ab94216 is a 293T cell transfected lysate in which Human Alpha 1 Acid Glycoprotein has been transiently over-expressed using a pCMV-Alpha 1 Acid Glycoprotein plasmid. The lysate is provided in 1X Sample Buffer.

Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Alpha 1 Acid Glycoprotein also known as AGP or Alpha 1 Glycoprotein is a plasma protein with a molecular weight of approximately 41 to 43 kDa. This protein circulates primarily in the bloodstream and is produced mainly by the liver. AGP is known for its highly glycosylated structure carrying several branched oligosaccharide chains. It exhibits a significant capacity to bind various endogenous and exogenous lipophilic substances influencing their transport and distribution in the body.
Biological function summary
AGP plays a role in modulating the immune response and maintaining homeostasis. As an acute-phase protein its levels rise significantly during inflammation infection and trauma where it acts to modulate the immune system. AGP does not exist as part of a larger protein complex but interacts with plasma lipoproteins and other glycoproteins aiding in its function of maintaining vascular integrity during acute-phase reactions.
Pathways
Alpha 1 Glycoprotein serves as an important component in the inflammatory response and drug-binding pathways. In the inflammatory pathway AGP interacts with cytokines and acute-phase reactants adjusting the body’s inflammatory processes. It is also involved in the binding and distribution of drugs interacting with albumin and other transport proteins to influence the pharmacokinetics of many medications.
AGP levels change in response to conditions like rheumatoid arthritis and liver diseases. In rheumatoid arthritis its increased levels correlate with disease activity and inflammation. In liver diseases the production and plasma concentration of AGP can reflect hepatic synthesis capability. AGP's interaction with cytokines in these conditions often links it to elevated levels of other acute-phase proteins like C-reactive protein reflecting its participation in the pathophysiological processes of inflammation.